Compare Five9 Inc (FIVN) vs Repligen Corporation Common Stock (RGEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Five9 Inc vs Repligen Corporation Common Stock — how do they compare? Five9 Inc trades at $33.37 (market cap $2.47B), while Repligen Corporation Common Stock trades at $178.2 (market cap $11.31B). The key difference: Repligen Corporation Common Stock is far larger — about 4.6× Five9 Inc's market cap, and Five9 Inc is more actively traded (1,632,106 versus 1,216,919). Which is the better fit depends on your goals — on Pluang, investors hold Five9 Inc for 72 Days and Repligen Corporation Common Stock for 0 Days on average.
| FIVN | RGEN | |
|---|---|---|
Market Cap | $2.47B | $11.31B |
Volume | 1,632,106 | 1,216,919 |
Sector | Technology | Health |
52-Week High | $38.65 | $194.57 |
52-Week Low | $13.61 | $102.87 |
Typical Hold Time | 72 Days | 0 Days |
Enterprise Value | $2.62B | $11.20B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Five9 (FIVN) trades at $35.41, down 0.73% on the day, with strong technical momentum showing bullish moving averages and neutral oscillators. The company demonstrates accelerating revenue growth, reaching $1.15B in 2025 with improving profitability as net income turned positive at $39.42M. Recent AI revenue surged 78% to $39M, now representing 15% of subscription revenue, driving investor optimism.
The outlook remains positive with analyst consensus at Buy (61%) and $34 price target, though current price exceeds consensus. Key risks include competitive CCaaS market pressure and insider selling activity. Revenue growth momentum and AI adoption provide upside potential, but valuation multiples remain elevated with P/E of 52 requiring sustained execution.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Five9 Inc
Five9 provides cloud-native contact center software that enables digital customer service, sales, and marketing engagement. The company's Virtual Contact Center platform combines core telephony functionality, omnichannel engagement capabilities, and various software modules into a unified cloud contact-center-as-a-service, or CCaaS, platform. Five9's artificial intelligence and automation portfolio supplements and enhances the firm's core CCaaS offerings, including solutions for digital self-service, agent assist technology, and workflow automation. Five9 also offers workforce optimization products that optimize call center efficiency through workforce management solutions, manage interaction quality, and track agent performance.
Read more on FIVN →About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →
